Skip to main content

In vivo molecular imaging with adjustable oligonucleotide ligands

Objective

Our aim is to link non-invasive imaging and nucleic acid biotechnology to create new in vivo imaging methods. Oligonucleotide ligands termed aptamers bind with high affinity biological targets and can be obtained from large combinatorial libraries. Modified aptamers engineered to resist degradation and target molecular markers of disease are thus promising candidates both as diagnostic tools and as therapeutic agents. Using non-invasive imaging procedures (PET) , we will evaluate in animal models of disease the potential of stable aptamers for diagnostic and therapy. This project merges 6 groups specialized in the following fields:
i) biologically-stable aptamer production (including a leading biotech company);
ii) study of biomarkers in animal disease models, and
iii) in vivo imaging methods. The major spin-off expected is the creation of generic methods for diagnosis and evaluation of new therapies.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

UNIVERSITE DE PARIS-SUD XI
Address
Rue Georges Clemenceau 15
91405 Orsay
France

Participants (6)

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
France
Address
Avenue De La Terrasse, Bftiment 26
91198 Gif Sur Yvette
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Spain
Address
Rosello 161
08036 Barcelona
HOSPITAL CLINIC BARCELONA
Spain
Address
Villaroel 170
08036 Barcelona
NATIONAL RESEARCH COUNCIL OF ITALY
Italy
Address
Via Sergio Pansini 5
80131 Napoli
NOXXON PHARMA AG
Germany
Address
Gustav-meyer-allee 25
13355 Berlin
UNIVERSITY OF TORINO
Italy
Address
Via Santena 19
10126 Torino (Turin)